Management of difficult germ-cell tumors.
Although testicular cancer is a rare disease accounting for only 1% of all male neoplasms, it represents a paradigm for cancer curability. Overall, more than 95% of patients can expect to be cured of their disease with minimal long-term toxicity. Given these expectations, it is critical that cancer care providers are familiar with the diagnostic and therapeutic challenges encountered in these rare patients. In particular, clinicians managing these patients should be aware of some of the pitfalls encountered when determining relapse. In a series of case presentations, we review the evaluation and management of patients with persistent elevation of serum tumor markers and postchemotherapy residual radiographic abnormalities.
Moore
Christie J
CJ
Department of Medicine, Division of Hematology/Oncology, Oregon Health and Science University, Portland, Oregon, USA.
Daneshmand
Siamak
S
Kondagunta
G Varuni
GV
Nichols
Craig R
CR
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D018450:Disease Progression; D006801:Humans; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000175:diagnosis* / Q000188:drug therapy* / Q000601:surgery; D011364:Professional Practice; D012008:Recurrence; D013736:Testicular Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000601:surgery; D016896:Treatment Outcome